OncoCyte (OCX)
(Delayed Data from NSDQ)
$3.24 USD
+0.07 (2.05%)
Updated Jul 23, 2024 03:59 PM ET
After-Market: $3.22 -0.02 (-0.46%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
OncoCyte Corporation [OCX]
Reports for Purchase
Showing records 1 - 20 ( 28 total )
Company: OncoCyte Corporation
Industry: Medical Services
Company: OncoCyte Corporation
Industry: Medical Services
Company: OncoCyte Corporation
Industry: Medical Services
Reimbursement Push to Generate Cash in FY22-FY24
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: OncoCyte Corporation
Industry: Medical Services
Company: OncoCyte Corporation
Industry: Medical Services
DetermaIO and TheraSure Focus to Conserve Cash in 1Q Update
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: OncoCyte Corporation
Industry: Medical Services
Company: OncoCyte Corporation
Industry: Medical Services
Cancer Dx Progression; Capital Requirements; Reduce to Sector Weight
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: OncoCyte Corporation
Industry: Medical Services
Company: OncoCyte Corporation
Industry: Medical Services
Expanding Molecular Diagnostic Portfolio in 3Q
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: OncoCyte Corporation
Industry: Medical Services
Company: OncoCyte Corporation
Industry: Medical Services
Company: OncoCyte Corporation
Industry: Medical Services
Company: OncoCyte Corporation
Industry: Medical Services
Company: OncoCyte Corporation
Industry: Medical Services
ASCO Annual Meeting: Compelling Picture of Molecular Diagnostic Future
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: OncoCyte Corporation
Industry: Medical Services
Company: OncoCyte Corporation
Industry: Medical Services
1Q Results with Compelling Dx Portfolio Outlook
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: OncoCyte Corporation
Industry: Medical Services
Company: OncoCyte Corporation
Industry: Medical Services
4Q Results with Upcoming DetermaIO Data
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: OncoCyte Corporation
Industry: Medical Services
Company: OncoCyte Corporation
Industry: Medical Services
Releasing New Model for Chronix M&A and DetermaRx Momentum; Raise PT to $7
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department